Peer Discussion Addresses Challenges in Recurrent Endometrial Cancer Treatment
Roundtable Roundup: February | Biliary Tract Cancer
Lipson Considers Tolerability When Selecting Immunotherapy for Metastatic Melanoma
Shahin Analyzes Benefits of Individualized Dosing With PARP Inhibitors in Advanced Ovarian Cancer
Worth The Wait? Genomic Testing Delays Initiation of Advanced NSCLC Therapy
Second-Generation BTK Inhibitor With Anti-CD20 Antibody Improves Survival and Responses in Treatment-Naive CLL
Neoadjuvant Treatment Shifts Standards of Care in Frontline NSCLC
Targeting GPRC5D Impacts Survival of Heavily Pretreated Patients With Relapsed/Refractory Multiple Myeloma